A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.

Item

http://www.wikidata.org/entity/Q34499662

Q34499662

about

The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges Maximising the potential of AKT inhibitors as anti-cancer treatments Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon.A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization.Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review.Akt inhibitor MK-2206 enhances the effect of cisplatin in gastric cancer cells.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies IGF-binding protein 2 is a candidate target of therapeutic potential in cancer.Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape.Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas.TMED2 promotes epithelial ovarian cancer growth.Evaluation of a developmental hierarchy for breast cancer cells to assess risk-based patient selection for targeted treatment.AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity.Dose-finding designs for trials of molecularly targeted agents and immunotherapies.Akt2/ZEB2 may be a biomarker for exfoliant cells in ascitic fluid in advanced grades of serous ovarian carcinoma.

P2860

Q26851852-E9DE84E6-DB3C-4995-80FC-53408E658CB5 Q28072254-BB8AA099-CF98-4993-8626-5F3237EB83BF Q28088432-F5B95DEF-AC83-4617-9423-4D429737EAC3 Q33423967-FE1AE87D-FB69-4888-AD0D-0996CC9D1A18 Q33435808-68611DCE-1AA3-495C-8BA9-6762FC618F2E Q35919248-FCAF5236-EC36-4663-B4B4-B3A9F1C3D06E Q36206239-ACAEF4E0-F5AE-4339-8BAC-9C6173EF58C0 Q36640092-E21BE54E-85E2-4BA5-BF4A-5B85E9F3D1BE Q36854062-1BB9A530-C4A3-496A-8D3A-EC297F729951 Q37641562-7CDEE878-86C4-44CE-8CB7-9C4EB47764AA Q38527936-3F8B4E0C-12CD-4C32-8582-367EC22E7AEF Q38641329-054028B6-AB77-4194-8234-10F26849D2F6 Q38667847-0DE31520-F21B-4676-A9DD-E63568B1D688 Q38784119-6643BBA1-E619-45BB-AC48-1DCB62A475D4 Q38813996-F30793C9-F369-4116-9263-FA1B29E370A8 Q38826826-B5BD7C06-1120-46C1-BADB-BD2F9AD8C520 Q38838220-3895C621-5D6B-42F5-B508-ECD7ACC6D7CB Q47145289-BF65D756-635E-4BED-B03B-0C16BBE51106 Q49307714-7D354600-499A-4595-BCCC-EE8664CB6105 Q51736090-D11663E9-45FD-4391-BD1E-DF6452D54F22 Q53522981-DAFF124E-3C9B-4B75-B4D2-E4F9E57E89B5 Q53536514-89C21F0F-444B-4432-9846-4A76D77EA027

P2860

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.

Item

http://www.wikidata.org/entity/Q34499662

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu